iShares Nasdaq BioTech ETF

IBB-Q

NASDAQ:IBB

136.49
0.34 (0.25%)

Analysis and Opinions about IBB-Q

Signal
Opinion
Expert
PARTIAL BUY
PARTIAL BUY
June 25, 2015

Within the healthcare space, biotech is one of the better valued areas. When you look at some of the names, they offer very good value as well as very good growth. This one has done well, so layer into it at this time.

Show full opinionHide full opinion

Within the healthcare space, biotech is one of the better valued areas. When you look at some of the names, they offer very good value as well as very good growth. This one has done well, so layer into it at this time.

HOLD
HOLD
June 4, 2015

The only knock that anybody can have about this is that it keeps going higher. The names it holds has to keep going through new highs. If you have owned this for a long time, the selling strategy is to bring it back if it has become too large a portion of your portfolio. Also, you have probably made a lot of money on the currency if you have owned it for a long time. He likes the diversity.

Show full opinionHide full opinion

The only knock that anybody can have about this is that it keeps going higher. The names it holds has to keep going through new highs. If you have owned this for a long time, the selling strategy is to bring it back if it has become too large a portion of your portfolio. Also, you have probably made a lot of money on the currency if you have owned it for a long time. He likes the diversity.

HOLD
HOLD
May 25, 2015

Biotechs mostly don’t pay dividends. When you get into a growth and momentum trade and the stock has doubled in a year or two, then it is not sustainable. He feels there is no value here. Look to take money off the table at some point, not put money in.

Show full opinionHide full opinion

Biotechs mostly don’t pay dividends. When you get into a growth and momentum trade and the stock has doubled in a year or two, then it is not sustainable. He feels there is no value here. Look to take money off the table at some point, not put money in.

COMMENT
COMMENT
May 8, 2015

This is a biotech ETF, and would be the main one he would look at for this sector.

Show full opinionHide full opinion

This is a biotech ETF, and would be the main one he would look at for this sector.

COMMENT
COMMENT
April 24, 2015

The month of May is probably one of the strongest months of the year for biotechs. The industry gains about 70% of the time for the month of May. Everything NASDAQ related tends to do well from about mid April all the way through to about mid July. The more predominant period of seasonal strength, which he tends to play, is from about mid June all the way through to September.

Show full opinionHide full opinion

The month of May is probably one of the strongest months of the year for biotechs. The industry gains about 70% of the time for the month of May. Everything NASDAQ related tends to do well from about mid April all the way through to about mid July. The more predominant period of seasonal strength, which he tends to play, is from about mid June all the way through to September.

TOP PICK
TOP PICK
April 21, 2015

One of his core themes for the last couple of years has been biotech. There are all kinds of new products coming down the pipe, with companies that are not terribly expensive. This is a way to get broad exposure to the sector without taking the binary risk that comes in some of the earlier stage companies.

Show full opinionHide full opinion

One of his core themes for the last couple of years has been biotech. There are all kinds of new products coming down the pipe, with companies that are not terribly expensive. This is a way to get broad exposure to the sector without taking the binary risk that comes in some of the earlier stage companies.

COMMENT
COMMENT
December 19, 2014

When you look at the largest companies in this, it is Amgen, Gilead Sciences, etc. He recently shorted this in his hedge fund as he thought it was a little stretched on valuations. If you want to play big biotech and growth biotech this is a good one.

Show full opinionHide full opinion

When you look at the largest companies in this, it is Amgen, Gilead Sciences, etc. He recently shorted this in his hedge fund as he thought it was a little stretched on valuations. If you want to play big biotech and growth biotech this is a good one.

BUY
BUY
July 11, 2014

Chart shows the trend is upward. Outperforming the market and above its 20 day moving average. Everything looks great on a technical basis. Seasonally, this usually does very well from around the latter part of June right through until September. A lot of this positive movement has to do with a series of healthcare conferences, which are held where biotech companies announce new results and new research.

Show full opinionHide full opinion

Chart shows the trend is upward. Outperforming the market and above its 20 day moving average. Everything looks great on a technical basis. Seasonally, this usually does very well from around the latter part of June right through until September. A lot of this positive movement has to do with a series of healthcare conferences, which are held where biotech companies announce new results and new research.

BUY
BUY
April 9, 2014

.4% expense ratio. He likes it. 122 holdings.

Show full opinionHide full opinion

.4% expense ratio. He likes it. 122 holdings.

DON'T BUY
DON'T BUY
March 5, 2014

42 times earnings so it is rich, but Biotech stocks always are. The price is way above the 200 day moving average. Likes the ETF, but it is expensive.

Show full opinionHide full opinion

42 times earnings so it is rich, but Biotech stocks always are. The price is way above the 200 day moving average. Likes the ETF, but it is expensive.

COMMENT
COMMENT
February 6, 2014

An example of a sector that has been considered to be expensive for the better part of 3-4 years. Not sure of their specific holdings but would imagine they have Biogenic, Biodex, Celgene, etc. This is an example of something he continues to own but doesn’t pretend to know enough about some of their individual companies. A perfect example of companies that you would want to own inside an ETF structure. Thinks it continues to go higher.

Show full opinionHide full opinion

An example of a sector that has been considered to be expensive for the better part of 3-4 years. Not sure of their specific holdings but would imagine they have Biogenic, Biodex, Celgene, etc. This is an example of something he continues to own but doesn’t pretend to know enough about some of their individual companies. A perfect example of companies that you would want to own inside an ETF structure. Thinks it continues to go higher.

BUY
BUY
October 15, 2013

Biotech ETF. You have to go with the IBB-N because we don’t have a Canadian one.

Show full opinionHide full opinion

Biotech ETF. You have to go with the IBB-N because we don’t have a Canadian one.

COMMENT
COMMENT
February 3, 2012
Nasdaq BioTech ETF. Certainly looks like it is breaking out. About 60% Biotech and 40% Pharma. Would have no problem going into this sector. Ilways a little concerned about going into something like this with US’s but with the Cdn$ doing so well, it might not be a problem.
Show full opinionHide full opinion
Nasdaq BioTech ETF. Certainly looks like it is breaking out. About 60% Biotech and 40% Pharma. Would have no problem going into this sector. Ilways a little concerned about going into something like this with US’s but with the Cdn$ doing so well, it might not be a problem.
PAST TOP PICK
PAST TOP PICK
October 7, 2011
(A Top Pick June 30/11. Down 11.5%.) Started doing okay but then the seasonal trade started to go against him so he got out.
Show full opinionHide full opinion
(A Top Pick June 30/11. Down 11.5%.) Started doing okay but then the seasonal trade started to go against him so he got out.
TOP PICK
TOP PICK
June 30, 2011
Nasdaq Biotechnology ETF, which has a seasonal strength from June 23 two the 2nd week of September. This is because of a series of healthcare conferences that happen at this time of year.
Show full opinionHide full opinion
Nasdaq Biotechnology ETF, which has a seasonal strength from June 23 two the 2nd week of September. This is because of a series of healthcare conferences that happen at this time of year.
Showing 46 to 60 of 66 entries